AstraZeneca Licenses Preclinical NASH Candidate from Partner Ionis

By Heather Cartwright

Pharma Deals Review: Vol 2018 Issue 4 (Table of Contents)

Published: 20 Apr-2018

DOI: 10.3833/pdr.v2018.i4.2321     ISSN: 1756-7874

Section: Licensing



In the latest deal in the crowded non-alcoholic steatohepatitis (NASH) field, AstraZeneca has licensed a preclinical antisense drug candidate from Ionis Pharmaceuticals for US$30 M upfront and up to US$300 M in development and regulatory milestone payments...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details